Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -206.32% is 525% below its 3-year average of -33.03%, near the low end of its 3-year range (-206.32%–0.00%).
288.22% below its 12-month average of -53.14%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -64.86%.
RETURN ON ASSETS (ROA)
-206.32%
RETURN ON ASSETS (ROA) AVG TTM
-53.14%
RETURN ON ASSETS (ROA) AVG 3Y
-33.03%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-288.22%
CURRENT VS 3Y AVG
-524.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-726.93%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.03M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
N/A
Market Cap
$6.88M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.76M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.74M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$6.72M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$6.44M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$6.34M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$7.75M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$7.77M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.03M | -206.32% | -53.14% | -33.03% | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -283.63% | -124.17% | -74.25% | -35.74% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -97.60% | -274.34% | -160.93% | -165.76% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -50.98% | -191.11% | -206.10% | -240.87% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -71.23% | -61.08% | -51.04% | -61.11% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -426.88% | -139.62% | -270.47% | -207.15% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -55.85% | -69.75% | -63.38% | -59.39% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -76.12% | -177.28% | -394.98% | -300.85% |
| GT Biopharma, Inc. (GTBP)vs › | $7.77M | -381.53% | -330.40% | -209.86% | -253.27% |
| Femasys Inc. (FEMY)vs › | $6.10M | -99.97% | -120.54% | -89.96% | -79.52% |
ROA
-206.3%
ROE
-218.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -36.49% |
| 2024-12-31 | -69.80% |
| 2023-12-31 | -25.82% |
| 2022-12-31 | 0.00% |
